Fig. 3: Therapeutic efficacy of GHP-88309 against recCDV-5804p NΔ425-479. | Nature Communications

Fig. 3: Therapeutic efficacy of GHP-88309 against recCDV-5804p NΔ425-479.

From: Therapeutic mitigation of measles-like immune amnesia and exacerbated disease after prior respiratory virus infections in ferrets

Fig. 3

a Schematic of therapeutic efficacy studies utilizing recCDV-5804p NΔ425-479. Symbols in the timeline refer to the different treatment groups or show nasal lavage sampling, respectively. b–k Survival curves (b), PBMC-associated viremia titers monitored until undetectable (c), CDV nasal lavage titers (d), lymphocyte counts (e), CDV-specific N RNA in circulating PBMCs of ferrets monitored until undetectable (f), CDV nAb titers (g), body temperature changes (h), RABV (i) and pdmCA09 (j) nAb titers, and pdmCA09 nasal lavage titers (k) after challenge of ferrets from (a) with pdmCA09 following recovery from CDV disease. Symbols represent geometric (d–g, i–k) or arithmetic (h) means ± geometric or arithmetic SD, lines intersect means; log-rank (Mantel-Cox) test, median survival is stated (b); mixed-effect analysis with Dunnett’s post-hoc test (c–e, g, i, j); 2-way ANOVA with Dunnett’s post-hoc test (f, h, k); multiplicity adjusted P values are shown; green shading in (e) denotes normal range; n numbers as specified. Source data are provided as a Source Data file.

Back to article page